Seeking Alpha · 4 Sept 2026neutral
LENZ Therapeutics received a 'Strong Buy' rating with a fair value estimate of $21.3, implying roughly 266% upside, with peak US Vizz sales modeled at $375M. However, the stock remains speculative due to single-product risk, high SG&A costs, its uninsured status, and rising competition, so the analysis keeps position sizing limited.
Why it matters — LENZ watchers would care because the analysis highlights both a large expected upside for Vizz and the key risks—single-product dependence, high expenses, lack of insurance coverage, and competition—that continue to make the stock speculative.
Seeking Alpha · 12 Aug 2026neutral
Seeking Alpha published the transcript of LENZ Therapeutics, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion of the company's second-quarter performance and outlook.
Why it matters — LENZ watchers would use the earnings call transcript to hear management's own commentary on quarterly results and guidance directly from the company.
MarketBeat · 11 Aug 2026positive
LENZ Therapeutics reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and increased prescription activity following the July rollout of national TV advertising and a telehealth access option.
Why it matters — The update offers LENZ watchers a closer look at early commercial traction for its product VIZZ, including revenue figures and prescription trends.
Zacks Investment Research · 11 Aug 2026neutral
LENZ Therapeutics reported a quarterly loss of $1.02 per share for Q2, which was narrower than the Zacks Consensus Estimate of a loss of $1.21, but wider than the year-ago loss of $0.53 per share. The company beat revenue estimates for the quarter.
Why it matters — The loss came in better than analysts expected even though it widened from the prior-year period, giving LENZ watchers a data point on the company's quarterly performance versus consensus.
GlobeNewsWire · 11 Aug 2026positive
LENZ Therapeutics reported financial results for the second quarter ended June 30, 2026, including total revenue of $5.5 million from VIZZ product sales and global license agreements. The company also noted strong patient persistence, with over 60% of patients in its dominant ePharmacy channel purchasing multiple monthly packs since launch, and reported that VIZZ prescription growth accelerated with the launch of its telehealth channel in July 2026.
Why it matters — The update provides LENZ watchers with a first look at the commercial performance and revenue from VIZZ since launch, along with signals on patient persistence and prescription growth.
